{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":13,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":13,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"6ac19511148b","filters":{"venue":"Section 4: Clinical pharmacy services"}},"results":[{"id":"W2944589946","doi":"10.1136/ejhpharm-2019-eahpconf.403","title":"4CPS-254 Biosimilar rituximab – a year beyond","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Kidney Foundation of Canada","keywords":"Biosimilar; Rituximab; Medicine; Discontinuation; Rheumatoid arthritis; Pharmacy; Retrospective cohort study; Internal medicine; Oncology; Lymphoma; Family medicine","authors":[{"name":"Mafalda Sá Pereira","is_ca":false},{"name":"Giovanna de Oliveira Sá Costa","is_ca":false},{"name":"S Domingos-Camões","is_ca":false},{"name":"A Alcobia","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03496363757777717,"gpt":0.3810492240157845,"spread":0.3460855864380074,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002853674,0.0002150294,0.0002851325,0.0006179478,0.0005213507,0.001514294,0.00046135,0.001306143,0.03324343],"category_scores_gemma":[0.004209328,0.0001093893,0.000549519,0.0006958432,0.0004679278,0.0008637526,0.0008316491,0.001402001,0.01086356],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001690533,"about_ca_system_score_gemma":0.001924171,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002425318,"about_ca_topic_score_gemma":0.001913402,"domain_scores_codex":[0.9982777,0.0003571129,0.0001869244,0.0001748118,0.0007589165,0.0002445343],"domain_scores_gemma":[0.9964461,0.000513843,0.000767984,0.0003276881,0.001069317,0.0008751564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.005972326,0.001335593,0.0838408,0.001004797,0.0002766961,0.005593663,0.00040866,0.0006077723,0.01591654,0.007783786,0.3062259,0.5710335],"study_design_scores_gemma":[0.0003777009,0.002110028,0.05712342,0.0005176091,0.00008207264,0.005753341,0.0002839934,0.0004761086,0.006690073,0.00140021,0.9251521,0.00003336838],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5483142,0.06919532,0.007478002,0.06588458,0.01537906,0.001179925,0.02739718,0.001549049,0.2636226],"genre_scores_gemma":[0.8097158,0.01438456,0.005469346,0.03050036,0.006385123,0.0003665404,0.02642331,0.0003738018,0.1063811],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03324343,"threshold_uncertainty_score":0.1112104,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4393026380","doi":"10.1136/ejhpharm-2024-eahp.245","title":"4CPS-141 Real-life impact of including montelukast as premedication on the incidence of infusion-related reactions to isatuximab and description of risk factors","year":2024,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Leslie Dan Faculty of Pharmacy, University of Toronto; University of Waterloo","keywords":"Discontinuation; Tolerability; Medicine; Regimen; Placebo; Premedication; Odds ratio; Adverse effect; Number needed to treat; Internal medicine; Confidence interval; Relative risk; Anesthesia","authors":[{"name":"MDC Jiménez León","is_ca":false},{"name":"JA Hernandez Ramos","is_ca":false},{"name":"M Martín Rodríguez","is_ca":false},{"name":"E Guerrero Hurtado","is_ca":false},{"name":"A Prieto Romero","is_ca":false},{"name":"F Mayo Olveira","is_ca":false},{"name":"Francisco Martínez de la Torre","is_ca":false},{"name":"MD Canales Siguero","is_ca":false},{"name":"JM Ferrari Piquero","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1080169857880549,"gpt":0.4437331214684653,"spread":0.3357161356804104,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001282214,0.0001824176,0.000338774,0.0004463394,0.0002450179,0.0006713332,0.0002312989,0.0004112711,0.00975364],"category_scores_gemma":[0.002512893,0.0001098931,0.0008239901,0.000645876,0.0001710019,0.0002514655,0.0003377918,0.0004358526,0.001407159],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000642361,"about_ca_system_score_gemma":0.001172652,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001767975,"about_ca_topic_score_gemma":0.001370682,"domain_scores_codex":[0.9991566,0.0003479298,0.0001402669,0.00009028149,0.000166909,0.00009802982],"domain_scores_gemma":[0.9961371,0.0007352934,0.001810633,0.0001994744,0.0005067487,0.0006106939],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01575932,0.001260565,0.8813012,0.0009840211,0.0004600276,0.0009482589,0.000187406,0.0006427547,0.002369742,0.0001832539,0.01192751,0.08397593],"study_design_scores_gemma":[0.0004686575,0.007125231,0.9775226,0.0002815996,0.0002741108,0.002029744,0.0002085812,0.0006385137,0.001339574,0.00009277078,0.009995801,0.00002272815],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806307,0.00351258,0.0005882509,0.0007391698,0.0001278169,0.0003213708,0.008363144,0.00008898565,0.005628058],"genre_scores_gemma":[0.9928817,0.0009235457,0.0007234953,0.000306474,0.000181172,0.0002074619,0.003354538,0.00001756033,0.001404056],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00975364,"threshold_uncertainty_score":0.03262919,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3016926053","doi":"10.1136/ejhpharm-2020-eahpconf.280","title":"4CPS-179 The wide review of polypharmacy in the frail older person","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; University Hospital Southampton NHS Foundation Trust","keywords":"Polypharmacy; Computer science; Older people; Gerontology; Medicine; Intensive care medicine","authors":[{"name":"Clare Kinahan","is_ca":false},{"name":"Helen Heery","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2952603473552379,"gpt":0.5051458419799638,"spread":0.2098854946247259,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007406414,0.0002039304,0.0004756455,0.002280078,0.001109937,0.002145752,0.000565322,0.001110119,0.02295087],"category_scores_gemma":[0.03668305,0.00025762,0.0007218437,0.002461813,0.0008208346,0.001455634,0.002393259,0.0007165007,0.002645911],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002879639,"about_ca_system_score_gemma":0.01431403,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009856039,"about_ca_topic_score_gemma":0.02127339,"domain_scores_codex":[0.9927593,0.004440845,0.0009730303,0.0002536052,0.001237855,0.0003352026],"domain_scores_gemma":[0.9669192,0.009969233,0.006313934,0.001704963,0.007517196,0.007575493],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"systematic_review","study_design_scores_codex":[0.001252251,0.001238024,0.134344,0.01152364,0.0004528557,0.0007719315,0.002226742,0.0002977677,0.001032312,0.002744667,0.2858974,0.5582184],"study_design_scores_gemma":[0.0008483163,0.003841258,0.5173557,0.01773369,0.0005029898,0.002552822,0.004146016,0.0006112985,0.0008425302,0.002299139,0.4491897,0.00007644884],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"review","genre_scores_codex":[0.4586933,0.1371786,0.004039727,0.1568435,0.00876755,0.009044091,0.02028291,0.0007016661,0.2044488],"genre_scores_gemma":[0.8545245,0.06295619,0.01141315,0.02771159,0.005807754,0.004687568,0.004984586,0.0001539137,0.02776073],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.02295087,"threshold_uncertainty_score":0.07677835,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4360614867","doi":"10.1136/ejhpharm-2023-eahp.52","title":"4CPS-003 Experiences with a best possible medication history (BPMH) conducted by pharmacy students in the hospital setting: a scoping review","year":2023,"lang":"en","type":"review","venue":"Section 4: Clinical pharmacy services","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Pharmacy; Patient safety; Medicine; Health care; Hospital pharmacy; MEDLINE; Clinical pharmacy; Family medicine; Medical education; Medical emergency","authors":[{"name":"Anita Elaine Weidmann","is_ca":false},{"name":"Julia Alexandra Schintler","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3738245371887848,"gpt":0.5799558731640854,"spread":0.2061313359753005,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03656114,0.001134415,0.003150389,0.01569686,0.002112175,0.005166708,0.002014676,0.003462186,0.01513819],"category_scores_gemma":[0.1064742,0.00128956,0.004802295,0.01496918,0.001543247,0.00430606,0.004839424,0.001691521,0.002201638],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006402981,"about_ca_system_score_gemma":0.02778922,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009423412,"about_ca_topic_score_gemma":0.01722373,"domain_scores_codex":[0.9693472,0.01339624,0.009443437,0.0008754921,0.006197819,0.0007397652],"domain_scores_gemma":[0.8949469,0.0699967,0.01022427,0.002038454,0.02131784,0.001475753],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0003405112,0.0001007587,0.002456887,0.8258491,0.001684532,0.0003131977,0.004015577,0.000128503,0.0003658735,0.001359519,0.026762,0.1366236],"study_design_scores_gemma":[0.00007766515,0.0001501588,0.002800249,0.9424033,0.001635702,0.000253208,0.001524304,0.00004004606,0.0001159547,0.0002124956,0.05076506,0.00002191223],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009684573,0.9468806,0.001164886,0.00830108,0.002523673,0.01279538,0.004881208,0.00009330356,0.01367519],"genre_scores_gemma":[0.03727679,0.9340601,0.004418171,0.0045121,0.0007021163,0.01433081,0.002939929,0.00005364873,0.001706319],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.03656114,"threshold_uncertainty_score":0.1933562,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3016600733","doi":"10.1136/ejhpharm-2020-eahpconf.281","title":"4CPS-180 From evidence based medicine to practice: gum chewing for postoperative recovery of gastrointestinal function after colorectal surgery with interprofessional teamwork","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Enhanced Recovery After Surgery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Queen's University Belfast; Queen's University; University Hospital Southampton NHS Foundation Trust","keywords":"Medicine; Randomized controlled trial; Colorectal surgery; Teamwork; Defecation; Colostomy; Physical therapy; Surgery; Abdominal surgery","authors":[{"name":"Yn Lin","is_ca":false},{"name":"CL Chuan","is_ca":false},{"name":"CS Tsai","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0752212007927984,"gpt":0.3995477239843968,"spread":0.3243265231915984,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01447205,0.00106964,0.00212203,0.007694511,0.001273046,0.004576459,0.001826328,0.005315219,0.03265403],"category_scores_gemma":[0.06126826,0.0007590229,0.005430025,0.005850141,0.001364352,0.003978393,0.003470275,0.003391375,0.004321296],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004700076,"about_ca_system_score_gemma":0.0163326,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003029616,"about_ca_topic_score_gemma":0.006421145,"domain_scores_codex":[0.9808891,0.009295868,0.005970463,0.0005064503,0.002994522,0.0003435673],"domain_scores_gemma":[0.9633601,0.01847957,0.00765197,0.001076068,0.007591615,0.00184066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.0009427264,0.0004653617,0.001681505,0.3810771,0.001761653,0.0003138433,0.0005420155,0.0002184107,0.0005365199,0.003031423,0.06017291,0.5492566],"study_design_scores_gemma":[0.002162971,0.001027794,0.01008745,0.8110643,0.003847264,0.000794719,0.0007065432,0.0002230015,0.000492326,0.004774817,0.1647502,0.00006865383],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.005727086,0.8705603,0.002348937,0.06396621,0.01179766,0.005929145,0.00189168,0.0001994278,0.03757951],"genre_scores_gemma":[0.05986392,0.861005,0.01974317,0.04058171,0.006266836,0.006057756,0.002121983,0.00008414086,0.004275455],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.03265403,"threshold_uncertainty_score":0.1092386,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3137967144","doi":"10.1136/ejhpharm-2021-eahpconf.232","title":"4CPS-400 The role and value of a ward based pharmacist in the intensive care unit: the critical care physicians’ and nurses’ perceptions","year":2021,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Likert scale; Pharmacist; Intensive care unit; Medicine; Scale (ratio); Nursing; Clinical pharmacy; Critical care nursing; Family medicine; Pharmacy; Psychology; Health care; Intensive care medicine","authors":[{"name":"DL Rayner","is_ca":false},{"name":"Louise Grech","is_ca":false},{"name":"Anthony Serracino‐Inglott","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1463255160144417,"gpt":0.5062585645855626,"spread":0.359933048571121,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003376818,0.0001831485,0.0001890432,0.0005351058,0.002434206,0.002851346,0.0005065804,0.001679432,0.01855596],"category_scores_gemma":[0.01123437,0.0001593752,0.0003146182,0.0007892009,0.002029534,0.001682705,0.001778831,0.001626541,0.002283284],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001897119,"about_ca_system_score_gemma":0.004424709,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.008611716,"about_ca_topic_score_gemma":0.009837716,"domain_scores_codex":[0.9971933,0.001395009,0.0002028209,0.00008358234,0.0008239399,0.0003014463],"domain_scores_gemma":[0.9886224,0.005035053,0.001123669,0.0001961785,0.002539399,0.002483456],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"qualitative","study_design_scores_codex":[0.0003106197,0.00101493,0.3971578,0.002618779,0.0000623084,0.00579275,0.3285681,0.0003395784,0.005382694,0.006454916,0.1235531,0.1287445],"study_design_scores_gemma":[0.00001737877,0.0006436061,0.3244968,0.001262766,0.00001951579,0.00217875,0.5952415,0.0003004532,0.0007675827,0.0008228457,0.07419781,0.00005102949],"study_design_candidate":"qualitative","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9097053,0.001160736,0.0008665343,0.03238585,0.001093411,0.0002041787,0.0005523429,0.00004456189,0.05398704],"genre_scores_gemma":[0.9838768,0.001179036,0.0007603682,0.005017376,0.0003374498,0.0001706899,0.0002340941,0.00002519953,0.008399038],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01855596,"threshold_uncertainty_score":0.06207591,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3138660907","doi":"10.1136/ejhpharm-2021-eahpconf.178","title":"4CPS-346 Evaluation of the implementation of ‘inhaler interviews’ during medication reconciliation in the pneumology service","year":2021,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Inhalation and Respiratory Drug Delivery","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Société de Pneumologie de Langue Française","keywords":"Inhaler; Checklist; Medicine; Pharmacy; Medical emergency; Physical therapy; Emergency medicine; Asthma; Nursing; Psychology; Internal medicine","authors":[{"name":"L Chebrek","is_ca":false},{"name":"Cecile Jonneaux","is_ca":false},{"name":"V Dehondt","is_ca":false},{"name":"P. Guillain","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1252837212849398,"gpt":0.4758899914348665,"spread":0.3506062701499267,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.05015971,0.0008065196,0.000726256,0.001095143,0.003322276,0.002104876,0.002228293,0.001422618,0.007983352],"category_scores_gemma":[0.08226667,0.0008223174,0.00106891,0.0009207969,0.001128703,0.001457103,0.004190513,0.001608602,0.001762885],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006327927,"about_ca_system_score_gemma":0.01624743,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01500343,"about_ca_topic_score_gemma":0.01889496,"domain_scores_codex":[0.9408149,0.05043059,0.002459803,0.0008984026,0.003003702,0.002392713],"domain_scores_gemma":[0.9288466,0.03562252,0.004846315,0.003136022,0.0151158,0.01243275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.009650001,0.0235572,0.1767158,0.006585394,0.0003129749,0.003984785,0.2394748,0.004104032,0.008902711,0.0008530015,0.02200125,0.5038581],"study_design_scores_gemma":[0.004703328,0.08933024,0.5216856,0.004936822,0.0005630411,0.00176539,0.2431977,0.01236729,0.01109795,0.0006619805,0.1090305,0.0006602535],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9698634,0.0002318333,0.004355466,0.002435048,0.0003152734,0.01161564,0.0008265059,0.0004753486,0.009881539],"genre_scores_gemma":[0.9524341,0.0003916021,0.02890631,0.001468976,0.0001548718,0.01231229,0.0007628457,0.0001092616,0.003459633],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05015971,"threshold_uncertainty_score":0.265273,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2921353678","doi":"10.1136/ejhpharm-2019-eahpconf.269","title":"4CPS-120 Erlotinib in non-small-cell lung cancer without epidermal growth factor receptor activating mutations","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Erlotinib; Medicine; Internal medicine; Epidermal growth factor receptor; Oncology; Lung cancer; Chemotherapy; Taxane; Erlotinib Hydrochloride; Adverse effect; Cancer; Breast cancer","authors":[{"name":"D Yáñez Feria","is_ca":false},{"name":"IM Carrión Madroñal","is_ca":false},{"name":"María Teresa Garrido Martínez","is_ca":false},{"name":"Olalla Montero Pérez","is_ca":false},{"name":"MD Santos Rubio","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03810566551067331,"gpt":0.4265117572884367,"spread":0.3884060917777634,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000600258,0.0001400378,0.0003975919,0.0002906953,0.0002097907,0.0003455224,0.0001742729,0.0003074211,0.00279577],"category_scores_gemma":[0.000570191,0.00008599959,0.0005306053,0.00054119,0.0002058662,0.0001969205,0.0002223133,0.0002719072,0.0006055702],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004158853,"about_ca_system_score_gemma":0.0007093833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001463682,"about_ca_topic_score_gemma":0.00258827,"domain_scores_codex":[0.9997061,0.00009995438,0.00005111016,0.00003160316,0.00005661098,0.00005462244],"domain_scores_gemma":[0.9995041,0.0001035569,0.0001944514,0.00003635941,0.00004793751,0.0001136245],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"not_applicable","study_design_scores_codex":[0.03553092,0.001911113,0.8036793,0.00117611,0.0004111246,0.002677371,0.0001775479,0.0006703644,0.01453353,0.0001937378,0.004801393,0.1342374],"study_design_scores_gemma":[0.003591359,0.02551783,0.9409249,0.0002294084,0.0004180968,0.008193136,0.0002004928,0.001246626,0.006795536,0.0001900535,0.01267367,0.00001894508],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952377,0.002169886,0.0001194485,0.0000920381,0.00001905217,0.00009861082,0.000940706,0.00001530896,0.001307239],"genre_scores_gemma":[0.9974081,0.0007673842,0.0001565427,0.0001116447,0.00002933831,0.00005881088,0.001063317,0.000004246616,0.000400543],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00279577,"threshold_uncertainty_score":0.009352744,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4293230261","doi":"10.1136/ejhpharm-2022-eahp.128","title":"4CPS-097 Role of the pharmacist in the care of the lung transplant patient","year":2022,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Transplantation: Methods and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Rio Tinto","keywords":"Medicine; Pharmacist; Lung transplantation; Bronchiectasis; Cystic fibrosis; Lung; Transplantation; Pulmonary function testing; Obstructive lung disease; Multidisciplinary team; Internal medicine; Physical therapy; Intensive care medicine; Pediatrics; COPD; Pharmacy; Family medicine; Nursing","authors":[{"name":"Ana Sangrador","is_ca":false},{"name":"V.M. Mora","is_ca":false},{"name":"Ruiz García. María","is_ca":false},{"name":"M Ramis","is_ca":false},{"name":"M Valero","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04133134081204663,"gpt":0.408605612208214,"spread":0.3672742713961674,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008005732,0.0001256629,0.0001903358,0.0004220373,0.0009463951,0.0009460701,0.0003164969,0.001156928,0.03634681],"category_scores_gemma":[0.002885958,0.0001205491,0.0002071032,0.0004095444,0.000265694,0.0005629095,0.000874589,0.0009859853,0.004576294],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007926815,"about_ca_system_score_gemma":0.0025829,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003391027,"about_ca_topic_score_gemma":0.00537994,"domain_scores_codex":[0.999377,0.0003117537,0.00005972664,0.00005007481,0.00008933512,0.0001122404],"domain_scores_gemma":[0.9958674,0.0005723392,0.0003840328,0.00007516827,0.0004352097,0.002665817],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007604874,0.00135947,0.337419,0.0008104416,0.0000746471,0.008515061,0.001014209,0.0002902843,0.001409644,0.000716689,0.1788518,0.4687782],"study_design_scores_gemma":[0.0004877773,0.00327887,0.6345533,0.002724404,0.0001140215,0.02631995,0.006651481,0.00139961,0.001241466,0.00100102,0.3221379,0.000090241],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5888271,0.02139265,0.001731622,0.1650951,0.004964855,0.0006706052,0.002697423,0.0007166105,0.2139041],"genre_scores_gemma":[0.9359785,0.01009653,0.003646527,0.02081152,0.004159442,0.0001971491,0.0008533797,0.00008591592,0.02417098],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03634681,"threshold_uncertainty_score":0.1215922,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4293230230","doi":"10.1136/ejhpharm-2022-eahp.129","title":"4CPS-099 Clinically relevant drug–drug interaction events in patients with abiraterone, enzalutamide or apalutamide treatment","year":2022,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Rio Tinto","keywords":"Enzalutamide; Medicine; Pharmacology; Prostate cancer; Drug interaction; Internal medicine; Drug; Cancer; Androgen receptor","authors":[{"name":"Julia Bodega-Azuara","is_ca":false},{"name":"Esther Vicente‐Escrig","is_ca":false},{"name":"T Cebolla-Beltrán","is_ca":false},{"name":"V Bosó-Ribelles","is_ca":false},{"name":"Josep Edo-Peñarrocha","is_ca":false},{"name":"M Fortanet-García","is_ca":false},{"name":"Raúl Ferrando‐Piqueres","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05257616929045679,"gpt":0.4169791532136755,"spread":0.3644029839232187,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008567742,0.0002495873,0.0005410549,0.00104784,0.0007279172,0.0009166888,0.0002870538,0.0008795714,0.01358039],"category_scores_gemma":[0.004245014,0.0001755406,0.0008705835,0.001604438,0.0002637646,0.0003639594,0.0008667218,0.000686158,0.001835377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009200006,"about_ca_system_score_gemma":0.002064927,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007727457,"about_ca_topic_score_gemma":0.008125573,"domain_scores_codex":[0.9984524,0.0004576977,0.0003767167,0.0001435754,0.0004054552,0.0001641773],"domain_scores_gemma":[0.9961213,0.0009378138,0.001621641,0.000151444,0.000470026,0.0006977619],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004434343,0.0003457981,0.8882746,0.001523906,0.0003217352,0.01104848,0.0003942987,0.0002985498,0.001549362,0.0004263906,0.0269158,0.0644666],"study_design_scores_gemma":[0.0004485171,0.001262031,0.9253725,0.0009383053,0.0002715469,0.01980407,0.0005221126,0.0008314629,0.001157899,0.000448715,0.04889413,0.00004873822],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8982599,0.01721342,0.001314032,0.00488644,0.0005186113,0.001004389,0.03319405,0.00031728,0.04329191],"genre_scores_gemma":[0.981136,0.002828368,0.0009308034,0.001472669,0.0002881442,0.0002275968,0.01008976,0.00003277648,0.002993749],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01358039,"threshold_uncertainty_score":0.0454309,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3016962124","doi":"10.1136/ejhpharm-2020-eahpconf.198","title":"4CPS-097 Secondline treatment of metastatic non-small cell lung cancer with immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Brain Metastases and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Rio Tinto","keywords":"Medicine; Pembrolizumab; Internal medicine; Oncology; Lung cancer; Nivolumab; Atezolizumab; Chemotherapy; Performance status; Retrospective cohort study; Cancer; Adverse effect; Immunotherapy","authors":[{"name":"FJ Salmeron Navas","is_ca":false},{"name":"C Martinez-Diaz","is_ca":false},{"name":"EM Barreiro-Fernandez","is_ca":false},{"name":"Mireia Cantero","is_ca":false},{"name":"S Fénix-Caballero","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05666603131101178,"gpt":0.381958387943695,"spread":0.3252923566326832,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001858653,0.0004067069,0.001246155,0.0006261292,0.0003322566,0.0006930748,0.0003972228,0.0009291038,0.01419815],"category_scores_gemma":[0.002626511,0.0001813873,0.002869704,0.0006232027,0.0003539491,0.0006685653,0.0004195853,0.0017221,0.001255794],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008513579,"about_ca_system_score_gemma":0.001103358,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001148711,"about_ca_topic_score_gemma":0.005437338,"domain_scores_codex":[0.9987485,0.0006952782,0.0001823666,0.000123865,0.0001688231,0.00008112151],"domain_scores_gemma":[0.9989643,0.0004312731,0.0002368266,0.00005363382,0.0001820163,0.0001319442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0873738,0.002983839,0.0065691,0.04938037,0.009459468,0.0002225305,0.0001588147,0.0009634386,0.006493407,0.001476793,0.02311732,0.811801],"study_design_scores_gemma":[0.4037785,0.1863242,0.06957273,0.03135037,0.02012103,0.002455821,0.000514928,0.002048798,0.01161774,0.002519232,0.2695515,0.0001450572],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"other","genre_scores_codex":[0.4850872,0.4203431,0.002426339,0.01083951,0.004700363,0.006859266,0.008909286,0.0004164821,0.06041845],"genre_scores_gemma":[0.9070287,0.06677804,0.002681601,0.005676565,0.0008855957,0.003131848,0.003807011,0.00003814756,0.00997252],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01419815,"threshold_uncertainty_score":0.04749757,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2945528492","doi":"10.1136/ejhpharm-2019-eahpconf.404","title":"4CPS-255 The effect of an enhancing medication adherence programme for a type 2 diabetes mellitus network","year":2019,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Medication Adherence and Compliance","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Chulabhorn Research Institute; Copperbelt University; Kidney Foundation of Canada","keywords":"Medicine; Pharmacist; Pharmacy; Test (biology); Family medicine; Type 2 Diabetes Mellitus; Diabetes mellitus","authors":[{"name":"T Pholchai","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07543680084374962,"gpt":0.4363149610199399,"spread":0.3608781601761902,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001805312,0.0002577718,0.0003839404,0.0003348502,0.001015306,0.000621269,0.000628855,0.0008681443,0.03061702],"category_scores_gemma":[0.00365595,0.0001694216,0.0008789863,0.0002820978,0.0001901167,0.0005012968,0.001512469,0.001237265,0.001745866],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009520244,"about_ca_system_score_gemma":0.00389709,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01149065,"about_ca_topic_score_gemma":0.0157498,"domain_scores_codex":[0.9988976,0.0006697188,0.00004759003,0.00006771193,0.0001225752,0.0001948093],"domain_scores_gemma":[0.9958842,0.0004673452,0.0002206402,0.0001501497,0.0002655675,0.003011953],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.02098852,0.0931367,0.06179557,0.002194194,0.0004298652,0.0004725024,0.0009977019,0.0006890208,0.001368377,0.0006478513,0.07202991,0.7452498],"study_design_scores_gemma":[0.03218393,0.1000794,0.7616923,0.002626979,0.0006929515,0.0003831664,0.002529459,0.001792521,0.001034632,0.0004731956,0.09644566,0.00006574531],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9198978,0.001704262,0.0004229592,0.01354906,0.002189761,0.0089907,0.003596505,0.0002906992,0.04935817],"genre_scores_gemma":[0.9267884,0.003095177,0.006961982,0.008909794,0.001979938,0.01051711,0.003678046,0.00006070958,0.03800874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03061702,"threshold_uncertainty_score":0.1024241,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4393005622","doi":"10.1136/ejhpharm-2024-eahp.183","title":"4CPS-079 Indirect comparison of il-13 inhibitors plus topical corticosteroids in moderate to severe atopic dermatitis","year":2024,"lang":"en","type":"article","venue":"Section 4: Clinical pharmacy services","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Medicine; Atopic dermatitis; Eczema Area and Severity Index; Dupilumab; Placebo; Corticosteroid; Internal medicine; Clinical endpoint; Gastroenterology; Randomized controlled trial; Dermatology","authors":[{"name":"FJ Salmerón-Navas","is_ca":false},{"name":"M Domínguez-Cantero","is_ca":false},{"name":"MA Blanco-Castaño","is_ca":false},{"name":"J Diaz-Navarro","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05583459261996076,"gpt":0.4134032319752196,"spread":0.3575686393552588,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005207848,0.0009136891,0.004353758,0.001794749,0.0003444796,0.001585793,0.0007823678,0.001364264,0.02515098],"category_scores_gemma":[0.007657217,0.0003594895,0.008201486,0.001752614,0.0006036723,0.0006965505,0.0007941831,0.001605427,0.001077439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001147659,"about_ca_system_score_gemma":0.001971708,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002021023,"about_ca_topic_score_gemma":0.004095872,"domain_scores_codex":[0.9918798,0.006072784,0.0009328476,0.0003027049,0.0006501057,0.0001618699],"domain_scores_gemma":[0.9960097,0.002449814,0.0007796891,0.0001574201,0.0003687599,0.0002344826],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7958171,0.001888326,0.001730628,0.0678646,0.05961473,0.0001479166,0.0001123309,0.0009415472,0.002697723,0.001037358,0.002167422,0.06598035],"study_design_scores_gemma":[0.6868584,0.1341797,0.01722269,0.00896884,0.1274085,0.0003453513,0.0002927485,0.00133734,0.001808544,0.001552552,0.01993772,0.00008747139],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5859678,0.3288783,0.004105546,0.00234365,0.005382282,0.02097685,0.02457675,0.0003308071,0.02743796],"genre_scores_gemma":[0.9342143,0.04439543,0.003557729,0.001087158,0.001034456,0.006168975,0.004254636,0.00003083256,0.005256393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02515098,"threshold_uncertainty_score":0.08413845,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}